John Farah
Director/Board Member at AEOLUS PHARMACEUTICALS, INC.
Net worth: 1 339 $ as of 2024-03-30
Profile
John Mitchell Farah is an Independent Director at Aeolus Pharmaceuticals, Inc. since 2011.
He is also a Director at Pond Technologies Holdings, Inc. since 2021.
Previously, he served as an Independent Director at Rebus Holdings, Inc. from 2008 to 2010.
He was the VP-International Pharmaceutical Operations at Cephalon, Inc. from 1992 to 2011.
He also held positions at Melior Discovery, Inc. as Chief Business Officer and at G.D.
Searle & Co., Inc. as a Discovery Research Scientist.
Dr. Farah completed his undergraduate studies at New College of California and the University of Maryland.
He obtained a doctorate degree from the Uniformed Services University of the Health Sciences in 1985.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-30 | 63,782 ( 0.09% ) | 1 339 $ | 2024-03-30 |
John Farah active positions
| Companies | Position | Start |
|---|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Director/Board Member | 2005-10-23 |
| POND TECHNOLOGIES HOLDINGS INC. | Director/Board Member | 2021-07-13 |
Former positions of John Farah
| Companies | Position | End |
|---|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | - |
| REBUS HOLDINGS, INC. | Director/Board Member | 2010-08-16 |
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Director/Board Member | 2013-01-15 |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Chief Tech/Sci/R&D Officer | - |
Training of John Farah
| New College of California | Undergraduate Degree |
| University of Maryland | Undergraduate Degree |
| Uniformed Services University of the Health Sciences | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| REBUS HOLDINGS, INC. | Health Technology |
| AEOLUS PHARMACEUTICALS, INC. | Health Technology |
| POND TECHNOLOGIES HOLDINGS INC. | Health Technology |
| Private companies | 3 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
- Stock Market
- Insiders
- John Farah
